• +86-0635-6175299
  • li_ye@inyelchem.com
  • Company Details

 Shandong Haohong Biotechnology Co., Ltd.

All
  • All
  • Title
All
  • All
  • Title
HomeProductsMigraine DrugRimegepant Intermediates
PRODUCT CATEGORIES

Rimegepant Intermediates

(Total 5 Products)
Pharmaceutical Raw Material Cas 1373116-06-3

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: 1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; EOS-60326;1-[1-(imidazole-1-carbonyl)piperidin-4-yl]-3H-imidazo[4,5-b]pyridin-2-one;...
Pharmaceutical Raw Material Cas 1190363-45-1

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: (R)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one; (R)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one;...
Rimegepant Intermediate Cas 1190363-45-1

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: (R)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one; (R)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one;...
Rimegepant Intermediate Cas 1373116-06-3

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: 1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; EOS-60326;1-[1-(imidazole-1-carbonyl)piperidin-4-yl]-3H-imidazo[4,5-b]pyridin-2-one;...
Rimegepant Intermediate Cas 1190363-46-2

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: (6S,9R)-6-(2,3-difluorophenyl)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-5-one; (6S,9R)-6-(2,3-Difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one;...
Home > Products > Migraine Drug > Rimegepant Intermediates

China Rimegepant Intermediates Suppliers

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] are the only members of the "gepants" family of medications remaining in development, and the only CGRP antagonists that possess oral bioavailability. The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.

Home

Product

Whatsapp

About Us

Inquiry

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Send